Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hu14.18-IL2 in Advanced Melanoma
NCT00109863Phase 2Completed
- Sponsor
- University of Wisconsin–Madison
- Start
- May 2005
- Primary completion
- Jul 2007
- Modality
- Immunomodulatory ADCs, Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of Lorukafusp alfa in melanoma, sponsored by University of Wisconsin–Madison. Started May 2005; status: completed.
02
Drugs
Lorukafusp alfa
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00109863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00109863.